Successful discontinuation of tyrosine kinase inhibitors has been achieved in patients with chronic-phase chronic myeloid leukemia (CML). Careful molecular monitoring after discontinuation warrants safe and prompt resumption of therapy. We retrospectively evaluated how molecular monitoring has been conducted in Italy in a cohort of patients who discontinued tyrosine kinase inhibitor (TKI) treatment per clinical practice. The outcome of these patients has recently been reported-281 chronic-phase CML patients were included in this subanalysis. Median follow-up since discontinuation was 2 years. Overall, 2203 analyses were performed, 17.9% in the first three months and 38.4% in the first six months. Eighty-six patients lost major molecular response (MMR) in a mean time of 5.7 months-65 pts (75.6%) during the first six months. We evaluated the number of patients who would experience a delay in diagnosis of MMR loss if a three-month monitoring schedule was adopted. In the first 6 months, 19 pts (29.2%) would have a one-month delay, 26 (40%) a 2-month delay. Very few patients would experience a delay in the following months. A less intense frequency of monitoring, particularly after the first 6 months off treatment, would not have affected the success of treatment-free remission (TFR) nor put patients at risk of progression.

A retrospective analysis about frequency of monitoring in Italian chronic myeloid leukemia patients after discontinuation / M. Dragani, G. Cambrin, P. Berchialla, I. Dogliotti, G. Rosti, F. Castagnetti, I. Capodanno, B. Martino, M. Cerrano, D. Ferrero, C. Gambacorti-Passerini, M. Crugnola, C. Elena, M. Breccia, A. Iurlo, D. Cattaneo, S. Galimberti, A. Gozzini, M. Bocchia, F. Lunghi, M. Cedrone, N. Sgherza, L. Luciano, S. Russo, M. Santoro, V. Giai, G. Caocci, L. Levato, E. Abruzzese, F. Sora, G. Saglio, C. Fava. - In: JOURNAL OF CLINICAL MEDICINE. - ISSN 2077-0383. - 9:11(2020 Nov 17), pp. 3692.1-3692.10. [10.3390/jcm9113692]

A retrospective analysis about frequency of monitoring in Italian chronic myeloid leukemia patients after discontinuation

D. Cattaneo;
2020-11-17

Abstract

Successful discontinuation of tyrosine kinase inhibitors has been achieved in patients with chronic-phase chronic myeloid leukemia (CML). Careful molecular monitoring after discontinuation warrants safe and prompt resumption of therapy. We retrospectively evaluated how molecular monitoring has been conducted in Italy in a cohort of patients who discontinued tyrosine kinase inhibitor (TKI) treatment per clinical practice. The outcome of these patients has recently been reported-281 chronic-phase CML patients were included in this subanalysis. Median follow-up since discontinuation was 2 years. Overall, 2203 analyses were performed, 17.9% in the first three months and 38.4% in the first six months. Eighty-six patients lost major molecular response (MMR) in a mean time of 5.7 months-65 pts (75.6%) during the first six months. We evaluated the number of patients who would experience a delay in diagnosis of MMR loss if a three-month monitoring schedule was adopted. In the first 6 months, 19 pts (29.2%) would have a one-month delay, 26 (40%) a 2-month delay. Very few patients would experience a delay in the following months. A less intense frequency of monitoring, particularly after the first 6 months off treatment, would not have affected the success of treatment-free remission (TFR) nor put patients at risk of progression.
chronic myeloid leukemia; treatment-free remission; molecular monitoring
Settore MED/15 - Malattie del Sangue
Article (author)
File in questo prodotto:
File Dimensione Formato  
Dragani M et al. J Clin Med 2020.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 603.94 kB
Formato Adobe PDF
603.94 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/859568
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 3
social impact